Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)

Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, Lionel D. Lewis, Todd M. Bauer, David F. McDermott, Michael Carducci, Christian Kollmannsberger, Brian I. Rini, Daniel Y.C. Heng, Jennifer Knox, Martin H. Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans Hammers

Research output: Contribution to journalComment/debate

Abstract

Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable." should be replaced with "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable." (3.0% instead of 0.3%). The publisher apologizes for any inconvenience caused by this error.

Original languageEnglish (US)
Article number73
JournalJournal for ImmunoTherapy of Cancer
Volume7
Issue number1
DOIs
StatePublished - Mar 14 2019

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Safety
Neoplasms
Publications
sunitinib
pazopanib
nivolumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Correction to : Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0). / Amin, Asim; Plimack, Elizabeth R.; Ernstoff, Marc S.; Lewis, Lionel D.; Bauer, Todd M.; McDermott, David F.; Carducci, Michael; Kollmannsberger, Christian; Rini, Brian I.; Heng, Daniel Y.C.; Knox, Jennifer; Voss, Martin H.; Spratlin, Jennifer; Berghorn, Elmer; Yang, Lingfeng; Hammers, Hans.

In: Journal for ImmunoTherapy of Cancer, Vol. 7, No. 1, 73, 14.03.2019.

Research output: Contribution to journalComment/debate

Amin, Asim ; Plimack, Elizabeth R. ; Ernstoff, Marc S. ; Lewis, Lionel D. ; Bauer, Todd M. ; McDermott, David F. ; Carducci, Michael ; Kollmannsberger, Christian ; Rini, Brian I. ; Heng, Daniel Y.C. ; Knox, Jennifer ; Voss, Martin H. ; Spratlin, Jennifer ; Berghorn, Elmer ; Yang, Lingfeng ; Hammers, Hans. / Correction to : Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0). In: Journal for ImmunoTherapy of Cancer. 2019 ; Vol. 7, No. 1.
@article{be219dca58c44291ad6e57f09a28545b,
title = "Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)",
abstract = "Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence {"}Two (6.1{\%}) patients achieved a complete response, 16 (48.5{\%}) achieved a partial response, 11 (33.3{\%}) had stable disease, one (0.3{\%}) had progressive disease, and in three patients (9.1{\%}), response was undeterminable.{"} should be replaced with {"}Two (6.1{\%}) patients achieved a complete response, 16 (48.5{\%}) achieved a partial response, 11 (33.3{\%}) had stable disease, one (3.0{\%}) had progressive disease, and in three patients (9.1{\%}), response was undeterminable.{"} (3.0{\%} instead of 0.3{\%}). The publisher apologizes for any inconvenience caused by this error.",
author = "Asim Amin and Plimack, {Elizabeth R.} and Ernstoff, {Marc S.} and Lewis, {Lionel D.} and Bauer, {Todd M.} and McDermott, {David F.} and Michael Carducci and Christian Kollmannsberger and Rini, {Brian I.} and Heng, {Daniel Y.C.} and Jennifer Knox and Voss, {Martin H.} and Jennifer Spratlin and Elmer Berghorn and Lingfeng Yang and Hans Hammers",
year = "2019",
month = "3",
day = "14",
doi = "10.1186/s40425-019-0559-3",
language = "English (US)",
volume = "7",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Correction to

T2 - Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)

AU - Amin, Asim

AU - Plimack, Elizabeth R.

AU - Ernstoff, Marc S.

AU - Lewis, Lionel D.

AU - Bauer, Todd M.

AU - McDermott, David F.

AU - Carducci, Michael

AU - Kollmannsberger, Christian

AU - Rini, Brian I.

AU - Heng, Daniel Y.C.

AU - Knox, Jennifer

AU - Voss, Martin H.

AU - Spratlin, Jennifer

AU - Berghorn, Elmer

AU - Yang, Lingfeng

AU - Hammers, Hans

PY - 2019/3/14

Y1 - 2019/3/14

N2 - Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable." should be replaced with "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable." (3.0% instead of 0.3%). The publisher apologizes for any inconvenience caused by this error.

AB - Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable." should be replaced with "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable." (3.0% instead of 0.3%). The publisher apologizes for any inconvenience caused by this error.

UR - http://www.scopus.com/inward/record.url?scp=85062998201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062998201&partnerID=8YFLogxK

U2 - 10.1186/s40425-019-0559-3

DO - 10.1186/s40425-019-0559-3

M3 - Comment/debate

C2 - 30871617

AN - SCOPUS:85062998201

VL - 7

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 73

ER -